The global geriatric medicines market predicted the growth at a CAGR of 6.1% over the forecast period from 2018 to 2026. With the vigorous CAGR, the market is expected to attain a value of US$ 1,080,696.6 mn by 2026 from a value of US$ 630,225.2 mn in 2017. Geriatric medicines are a specialty branch of medical science that provides diagnosis and treatment options for the elderly. Most geriatrics are unable to take their medication properly at a scheduled time, due to complex medical and psychological problems. The geriatric population requires special care and attention for the speedy recovery of disease or disorder. The global geriatric medicines market is expanding at a significant pace due to increasing government support toward old people for their health, safety, and nursing care. Developed nations already have quality geriatric care management systems in place and developing nations are making high investments in geriatric care.
The report analyzes and forecasts the geriatric medicines market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from 2019 to 2026. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level. For the region and all segments, the sales, revenue and their market share, growth rate are key research objects; we can research the manufacturers' sales, price, revenue, cost and gross profit and their changes. What's more, we will display the main consumers, raw material manufacturers, distributors, etc.
This report first introduces the background of geriatric medicines, including the definition, classification, application, industrial chain structure, industry overview, national policy and planning analysis of the industry, and the latest dynamic analysis. With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major geriatric medicines companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of geriatric medicines upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of geriatric medicines and consumption, major regions and consumption, major global producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The report comprises a detailed value chain analysis, which provides a comprehensive view of the global geriatric medicines market. The Porter’s Five Forces model has also been included to help understand the competitive landscape of the market. The study encompasses market attractiveness analysis, wherein various applications have been benchmarked based on their market size, growth rate, and general attractiveness.
The study provides a decisive view of the geriatric medicines market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The report provides size (in terms of volume and value) of geriatric medicines market for the base year 2018 and the forecast between 2019 and 2026. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
Companies Mentioned in Report
The report also profiles major players in the geriatric medicines market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include Pfizer, Inc., Merck & Co., Inc., AstraZeneca, Bristol-Myers Squibb Company, Novartis AG, Sanofi S.A., GlaxoSmithKline plc, Eli Lilly and Company, Abbott Laboratories, and Boehringer Ingelheim GmbH.
Report Segmentation:
Global Geriatric Medicines Market, by Therapeutic Category
Global Geriatric Medicines Market, by Condition
Global Geriatric Medicines Market, by Distribution Channel
Global Geriatric Medicines Market, by Region
Research Methodology:
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding.
Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.
The study objectives of this report are:
Section 1 Preface
1.1 Report Scope and Market Segmentation
1.2 Research Highlights
Section 2 Assumptions and Research Methodology
2.1 Assumptions
2.2 Research Methodology
Section 3 Executive Summary
3.1 Global Geriatric Medicines Market Snapshot
3.2 Global Geriatric Medicines Market Share Analysis, by Region, 2017
Section 4 Market Overview
4.1 Global Geriatric Medicines Market Taxonomy
4.2 Global Geriatric Medicines Market Value (US$ Mn) Forecast, 2018–2026
4.3 Global Geriatric Medicines Market: Market Outlook
4.4 Key Industry Events
Section 5 Market Dynamics
5.1 Drivers and Restraints Snapshot Analysis
5.2 Drivers
5.2.1 Increase in global geriatric population
5.2.2 Rise in chronic diseases (stroke, respiratory, and arthritis)
5.2.3 Increase in government support for elderly
5.2.4 Technological advancements for medication assistance
5.3 Restraints
5.3.1 Significant shortfall of geriatricians in the world
5.3.2 High chances of adverse drug reaction in elderly
5.3.3 Lack of patient participation in clinical trials
Section 6 Geriatric Medicines Market Analysis, by Therapeutic Category
6.1 Key Findings
6.2 Introduction
6.3 Global Geriatric Medicines Market Value Share Analysis, by Therapeutic Category
6.4 Global Geriatric Medicines Market Forecast, by Therapeutic Category
6.5 Global Geriatric Medicines Market Analysis, by Therapeutic Category
6.5.1 Analgesic
6.5.2 Antihypertensive
6.5.3 Statins
6.5.4 Antidiabetic
6.5.5 Proton Pump Inhibitor
6.5.6 Anticoagulant
6.5.7 Antipsychotic and Antidepressant
6.5.8 Others
Section 7 Global Geriatric Medicines Market Analysis, by Condition
7.1 Key Findings
7.2 Introduction
7.3 Global Geriatric Medicines Market Value Share Analysis, by Condition
7.4 Global Geriatric Medicines Market Forecast, by Condition
7.5 Global Geriatric Medicines Market Analysis, by Condition
7.5.1 Cardiovascular
7.5.2 Arthritis
7.5.3 Diabetes
7.5.4 Neurological
7.5.5 Cancer
7.5.6 Osteoporosis
7.5.7 Respiratory
7.5.8 Others
Section 8 Global Geriatric Medicines Market Analysis, by Distribution Channel
8.1 Key Findings
8.2 Introduction
8.3 Global Geriatric Medicines Market Value Share Analysis, by Distribution Channel
8.4 Global Geriatric Medicines Market Forecast, by Distribution Channel
8.5 Global Geriatric Medicines Market Analysis, by Distribution Channel
8.5.1 Hospital Pharmacies
8.5.2 Retail Pharmacies
8.5.3 Online Pharmacies
Section 9 Global Geriatric Medicines Market Analysis, by Region
9.1 Global Geriatric Medicines Market Value Share Analysis, by Region
9.2 Global Geriatric Medicines Market Forecast, by Region
Section 10 North America Geriatric Medicines Market Analysis, by Region
10.1 Market Overview
10.2 North America Geriatric Medicines Market Value Share and Attractiveness Analysis, by Country
10.3 North America Geriatric Medicines Market Value Share Analysis, by Therapeutic Category
10.4 North America Geriatric Medicines Market Forecast, by Therapeutic Category
10.5 North America Geriatric Medicines Market Value Share Analysis, by Condition
10.6 North America Geriatric Medicines Market Forecast, by Condition
10.7 North America Geriatric Medicines Market Value Share Analysis, by Distribution Channel
10.8 North America Geriatric Medicines Market Forecast, by Distribution Channel
10.9 North America Geriatric Medicines Market Value Share Analysis, by Country
10.10 North America Geriatric Medicines Market Forecast, by Country
10.10.1 U.S.
10.10.2 Canada
Section 11 Europe Geriatric Medicines Market Analysis, by Region
11.1 Market Overview
11.2 Europe Geriatric Medicines Market Value Share and Attractiveness Analysis, by Country/Sub-region
11.3 Europe Geriatric Medicines Market Value Share Analysis, by Therapeutic Category
11.4 Europe Geriatric Medicines Market Forecast, by Therapeutic Category
11.5 Europe Geriatric Medicines Market Value Share Analysis, by Condition
11.6 Europe Geriatric Medicines Market Forecast, by Condition
11.7 Europe Geriatric Medicines Market Value Share Analysis, by Distribution Channel
11.8 Europe Geriatric Medicines Market Forecast, by Distribution Channel
11.9 Europe Geriatric Medicines Market Value Share Analysis, by Country/Sub-region
11.10 Europe Geriatric Medicines Market Forecast, by Country/Sub-region
11.10.1 Germany
11.10.2 U.K.
11.10.3 France
11.10.4 Spain
11.10.5 Italy
11.10.6 Rest of Europe
Section 12 Asia Pacific Geriatric Medicines Market Analysis, by Region
12.1 Market Overview
12.2 Asia Pacific Geriatric Medicines Market Value Share and Attractiveness Analysis, by Country/Sub-region
12.3 Asia Pacific Geriatric Medicines Market Value Share Analysis, by Therapeutic Category
12.4 Asia Pacific Geriatric Medicines Market Forecast, by Therapeutic Category
12.5 Asia Pacific Geriatric Medicines Market Value Share Analysis, by Condition
12.6 Asia Pacific Geriatric Medicines Market Forecast, by Condition
12.7 Asia Pacific Geriatric Medicines Market Value Share Analysis, by Distribution Channel
12.8 Asia Pacific Geriatric Medicines Market Forecast, by Distribution Channel
12.9 Asia Pacific Geriatric Medicines Market Value Share Analysis, by Country/Sub-region
12.10 Asia Pacific Geriatric Medicines Market Forecast, by Country/Sub-region
12.10.1 China
12.10.2 Japan
12.10.3 India
12.10.4 Australia & New Zealand
12.10.5 Rest of APAC
Section 13 Latin America Geriatric Medicines Market Analysis, by Region
13.1 Market Overview
13.2 Latin America Geriatric Medicines Market Value Share and Attractiveness Analysis, by Country/Sub-region
13.3 Latin America Geriatric Medicines Market Value Share Analysis, by Therapeutic Category
13.4 Latin America Geriatric Medicines Market Forecast, by Therapeutic Category
13.5 Latin America Geriatric Medicines Market Value Share Analysis, by Condition
13.6 Latin America Geriatric Medicines Market Forecast, by Condition
13.7 Latin America Geriatric Medicines Market Value Share Analysis, by Distribution Channel
13.8 Latin America Geriatric Medicines Market Forecast, by Distribution Channel
13.9 Latin America Geriatric Medicines Market Value Share Analysis, by Country/Sub-region
13.10 Latin America Geriatric Medicines Market Forecast, by Country/Sub-region
13.10.1 Brazil
13.10.2 Mexico
13.10.3 Rest of LATAM
Section 14 Middle East & Africa Geriatric Medicines Market Analysis, by Region
14.1 Market Overview
14.2 Middle East & Africa Geriatric Medicines Market Value Share and Attractiveness Analysis, by Country/Sub-region
14.3 Middle East & Africa Geriatric Medicines Market Value Share Analysis, by Therapeutic Category
14.4 Middle East & Africa Geriatric Medicines Market Forecast, by Therapeutic Category
14.5 Middle East & Africa Geriatric Medicines Market Value Share Analysis, by Condition
14.6 Middle East & Africa Geriatric Medicines Market Forecast, by Condition
14.7 Middle East & Africa Geriatric Medicines Market Value Share Analysis, by Distribution Channel
14.8 Middle East & Africa Geriatric Medicines Market Forecast, by Distribution Channel
14.9 Middle East & Africa Geriatric Medicines Market Value Share Analysis, by Country/Sub-region
14.10 Middle East & Africa Geriatric Medicines Market Forecast, by Country/Sub-region
14.10.1 GCC
14.10.2 South Africa
14.10.3 Rest of MEA
Section 15 Company Profiles
15.2.1 Pfizer, Inc.
15.2.1.1 Company Overview (HQ, Business Segments, Employee Strength)
15.2.1.2 Financial Overview
15.2.1.3 Product Portfolio
15.2.1.4 SWOT Analysis
15.2.1.5 Strategic Overview
15.2.2 Merck & Co., Inc.
15.2.2.1 Company Overview (HQ, Business Segments, Employee Strength)
15.2.2.2 Financial Overview
15.2.2.3 Product Portfolio
15.2.2.4 SWOT Analysis
15.2.2.5 Strategic Overview
15.2.3 AstraZeneca
15.2.3.1 Company Overview (HQ, Business Segments, Employee Strength)
15.2.3.2 Financial Overview
15.2.3.3 Product Portfolio
15.2.3.4 SWOT Analysis
15.2.3.5 Strategic Overview
15.2.4 Bristol-Myers Squibb Company
15.2.4.1 Company Overview (HQ, Business Segments, Employee Strength)
15.2.4.2 Financial Overview
15.2.4.3 Product Portfolio
15.2.4.4 SWOT Analysis
15.2.4.5 Strategic Overview
15.2.5 Novartis AG
15.2.5.1 Company Overview (HQ, Business Segments, Employee Strength)
15.2.5.2 Financial Overview
15.2.5.3 Product Portfolio
15.2.5.4 SWOT Analysis
15.2.5.5 Strategic Overview
15.2.6 Sanofi S.A.
15.2.6.1 Company Overview (HQ, Business Segments, Employee Strength)
15.2.6.2 Financial Overview
15.2.6.3 Product Portfolio
15.2.6.4 SWOT Analysis
15.2.6.5 Strategic Overview
15.2.7 GlaxoSmithKline plc
15.2.7.1 Company Overview (HQ, Business Segments, Employee Strength)
15.2.7.2 Financial Overview
15.2.7.3 Product Portfolio
15.2.7.4 SWOT Analysis
15.2.7.5 Strategic Overview
15.2.8 Eli Lilly and Company
15.2.8.1 Company Overview (HQ, Business Segments, Employee Strength)
15.2.8.2 Financial Overview
15.2.8.3 Product Portfolio
15.2.8.4 SWOT Analysis
15.2.8.5 Strategic Overview
15.2.9 Abbott Laboratories
15.2.9.1 Company Overview (HQ, Business Segments, Employee Strength)
15.2.9.2 Financial Overview
15.2.9.3 Product Portfolio
15.2.9.4 SWOT Analysis
15.2.9.5 Strategic Overview
15.2.10 Boehringer Ingelheim GmbH
15.2.10.1 Company Overview (HQ, Business Segments, Employee Strength)
15.2.10.2 Financial Overview
15.2.10.3 Product Portfolio
15.2.10.4 SWOT Analysis
15.2.10.5 Strategic Overview
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers